Ifirmasta

Irbesartan, the active ingredient in Ifirmasta, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers blood pressure and protects kidney function in patients with hypertension and diabetic nephropathy. It works by selectively blocking the AT1 receptor, reducing vasoconstriction and aldosterone release, which contributes to its antihypertensive effect.

GNH USA supplies Ifirmasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Ifirmasta (irbesartan) is indicated for conditions involving the renin‑angiotensin system, primarily hypertension and diabetic kidney disease. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular events. - Diabetic nephropathy: slows progression of renal impairment in patients with type 2 diabetes. - Chronic kidney disease associated with hypertension: helps control blood pressure and reduce proteinuria in CKD patients.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: light‑headedness especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness. - Nasal congestion: stuffy nose. - Elevated serum potassium: mild hyperkalaemia. - Diarrhoea: loose stools. - Cough: mild throat irritation. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hyperkalaemia: markedly high potassium levels. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzymes. - Hypotension: excessive drop in blood pressure.

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Renal impairment: monitor kidney function and adjust dose in patients with reduced creatinine clearance. - Hyperkalaemia risk: check serum potassium before initiation and periodically during therapy. - Concomitant potassium‑sparing diuretics: avoid or use with caution to prevent excess potassium. - Volume depletion: assess for dehydration before starting treatment. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Irbesartan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment, hyperkalaemia and hypotension. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use can lead to additive effects on potassium and renal function.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and worsen renal function. - Lithium: may increase lithium levels, requiring serum monitoring. - Thiazide diuretics: can enhance antihypertensive effect and increase risk of low blood pressure. - Antidiabetic drugs: may need dose adjustment as blood pressure control can affect glucose metabolism.